Department of Hepato-Biliary-Pancreato-Vascular Surgery, the First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen 361003, Fujian Province, China.
Langenbecks Arch Surg. 2011 Oct;396(7):1109-17. doi: 10.1007/s00423-011-0784-9. Epub 2011 Apr 8.
The choice between anatomic resection (AR) versus nonanatomic resection (NAR) for hepatocellular carcinoma (HCC) is controversial. This study is a meta-analysis of the available evidence.
A systematic review and meta-analysis of trials comparing AR with NAR for HCC published from 1985 to 2009 in PubMed and Medline database, Cochrane database, Embase database, and Science Citation index were conducted. Overall survival, disease-free survival, and local recurrence rate were considered as primary outcomes. Pooled effect was calculated using either the fixed effects model or random effects model.
Sixteen nonrandomized studies involving 2,917 patients were analyzed; 1,577 patients were in the AR group, and 1,340 were in the NAR group. Patients in the AR group were characterized by lower prevalence of cirrhosis and hepatitis virus infection, more favorable hepatic function, and larger tumor size compared with patients in the NAR group. AR provided a better 5-year overall survival than NAR (OR, 1.63; 95% CI, 1.15-2.32). Local recurrence (OR, 0.28; 95% CI, 0.16-0.50) and early (≤2 years) recurrence (OR, 0.55; 95 CI, 0.34-0.89) were all significantly lower in the AR group. AR improved disease-free survival significantly at 3 years (OR, 2.09; 95% CI, 1.52-2.88) and 5 years (OR, 2.24; 95% CI, 1.85-2.72). No differences were found between the two groups with respect to postoperative morbidity, mortality, and length of hospital stay.
AR was superior to NAR in terms of better survival and preventing local recurrence for the treatment of HCC.
对于肝细胞癌(HCC),解剖性肝切除术(AR)与非解剖性肝切除术(NAR)的选择仍存在争议。本研究对现有证据进行了荟萃分析。
系统检索 1985 年至 2009 年PubMed、Medline、Cochrane 数据库、Embase 数据库和 Science Citation Index 中关于 AR 与 NAR 治疗 HCC 的临床试验,对纳入的研究进行荟萃分析。主要观察终点为总生存、无瘤生存和局部复发率。采用固定效应模型或随机效应模型计算合并效应。
共纳入 16 项非随机研究,2917 例患者,AR 组 1577 例,NAR 组 1340 例。AR 组患者的肝硬化和肝炎病毒感染发生率较低,肝功能较好,肿瘤较大。AR 组患者的 5 年总生存率明显优于 NAR 组(OR=1.63,95%CI:1.152.32)。AR 组局部复发(OR=0.28,95%CI:0.160.50)和早期(≤2 年)复发(OR=0.55,95%CI:0.340.89)均显著低于 NAR 组。AR 组患者在 3 年(OR=2.09,95%CI:1.522.88)和 5 年(OR=2.24,95%CI:1.85~2.72)时无瘤生存率显著提高。两组患者术后发病率、死亡率和住院时间差异无统计学意义。
AR 在提高生存率和预防局部复发方面优于 NAR,是治疗 HCC 的一种更优选择。